Source:http://linkedlifedata.com/resource/pubmed/id/19178667
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
2009-1-30
|
| pubmed:abstractText |
Cytosine arabinoside (ara-C) is a component of many protocols for the treatment of acute leukaemia and non-Hodgkin lymphomas in humans. The aim of the study was to prospectively evaluate the efficacy of ara-C in a myeloablative regimen in a cohort of canine lymphomas with bone marrow involvement. Seventeen dogs were enrolled. Eight were treated with a VCAA-based protocol (Group 1) and nine with the same regimen added with ara-C (Group 2). Ara-C was administered on a 5-day schedule as an i.v. continuous infusion at the dose of 150 mg m(-2) per day for five consecutive days. During treatment complete remission (CR) was achieved in two dogs in Group 1 and in eight dogs in Group 2. CR rate was significantly higher in Group 2 (P < 0.01). Median survival was 72.5 days (range 6-174) in Group 1 and 243 days (range 73-635) in Group 2. Survival was significantly longer in Group 2 (P < 0.001). Both protocols were well tolerated, with a low incidence of adverse events. Ara-C added to a VCAA-based protocol appears to be safe and beneficial in dogs with stage V lymphoma. Incorporation of the nucleoside analogue might be crucial for the development of future therapeutic strategies in dogs.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antimetabolites, Antineoplastic,
http://linkedlifedata.com/resource/pubmed/chemical/Asparaginase,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide,
http://linkedlifedata.com/resource/pubmed/chemical/Cytarabine,
http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Vincristine
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
1476-5829
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
6
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
80-9
|
| pubmed:meshHeading |
pubmed-meshheading:19178667-Animals,
pubmed-meshheading:19178667-Antimetabolites, Antineoplastic,
pubmed-meshheading:19178667-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:19178667-Asparaginase,
pubmed-meshheading:19178667-Bone Marrow Neoplasms,
pubmed-meshheading:19178667-Cyclophosphamide,
pubmed-meshheading:19178667-Cytarabine,
pubmed-meshheading:19178667-Dog Diseases,
pubmed-meshheading:19178667-Dogs,
pubmed-meshheading:19178667-Doxorubicin,
pubmed-meshheading:19178667-Female,
pubmed-meshheading:19178667-Lymphoma,
pubmed-meshheading:19178667-Male,
pubmed-meshheading:19178667-Neoplasm Staging,
pubmed-meshheading:19178667-Remission Induction,
pubmed-meshheading:19178667-Survival Analysis,
pubmed-meshheading:19178667-Treatment Outcome,
pubmed-meshheading:19178667-Vincristine
|
| pubmed:year |
2008
|
| pubmed:articleTitle |
Cytosine arabinoside in addition to VCAA-based protocols for the treatment of canine lymphoma with bone marrow involvement: does it make the difference?
|
| pubmed:affiliation |
Clinica Veterinaria L'Arca, Naples, Italy. lauramarconato@yahoo.it
|
| pubmed:publicationType |
Journal Article
|